Pegylated Interferon Alfa-2B

Adult T-cell Leukemia-Lymphoma

University of MiamiPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

38 Active assets in the Adult T-cell Leukemia-Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine John Reneau	Phase 2	BBB
Cyclophosphamide John Reneau	Phase 4	BBB
DEXAMETHASONE The First Affiliated Hospital of Soochow University	Phase 2	BBB
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BBB
cc-5013 National Cancer Institute (NCI)	Phase 2	BBB

View all 50 →

Same molecule, other indications

Pegylated Interferon Alfa-2B is also rated in:

chronic hepatitis C virus infectionDormant

BBB

Indicative ·

78 / 100

chronic hepatitis C virus infectionDormant

BB

Indicative ·

64 / 100

disease related to solid organ transplantationDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.